Arana updates inflammatory pipeline milestones

Biotechnology company Arana Therapeutics Limited today provided an update on the major inflammatory compounds in its drug development pipeline. As part of this update, Arana said it has developed a new antibody candidate ART123, targeting inflammatory diseases and it plans to start a Phase I clinical trial for age-related macular degeneration (AMD) candidate PMX53 in 2009.

ART123 was produced using Arana's proprietary antibody engineering technologies. Patents have been filed around the novel mechanism of action of ART123, which has demonstrated efficacy in a pre-clinical psoriasis model. Preclinical safety studies are expected to commence in 2010.

Arana has developed and tested several new formulations of PMX53 in animal models of AMD, psoriasis and osteoarthritis. The AMD clinical trial is expected to start in the first half of 2009, subject to the successful completion of ongoing pre-clinical dose-ranging studies. Data from long term pre-clinical osteoarthritis studies are also expected to be available in early 2009. Arana has no current plans for further development of the psoriasis indication.

Arana also said that lead compound ART621 continues to progress in its development with several major milestones expected in the next six months. These include an Investigational New Drug application (IND) for the rheumatoid arthritis indication in the fourth quarter of 2008, a Phase II study in rheumatoid arthritis planned to commence also in the fourth quarter of 2008, and safety and efficacy data from a psoriasis study expected in the first quarter of 2009.

Commenting on these developments, CEO John Chiplin said: "We are delighted with the progress in our inflammatory pipeline, with products targeting important and large disease markets where antibody products have revolutionised treatments."

"The addition of ART123 strengthens our portfolio and demonstrates the depth of our engineering technologies and intellectual property capabilities. We look forward to updating the market on our future progress especially in relation to ART621 which has several important milestones ahead including an IND submission in the next month or so," Dr Chiplin added.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management